We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed the most recent trading day at $26.21, moving -0.38% from the previous trading session. This move lagged the S&P 500's daily gain of 1.08%. Meanwhile, the Dow gained 0.92%, and the Nasdaq, a tech-heavy index, added 1.41%.
The the stock of drugmaker has risen by 2.93% in the past month, leading the Medical sector's gain of 0.21% and the S&P 500's loss of 8.26%.
The investment community will be closely monitoring the performance of Pfizer in its forthcoming earnings report. On that day, Pfizer is projected to report earnings of $0.67 per share, which would represent a year-over-year decline of 18.29%. Simultaneously, our latest consensus estimate expects the revenue to be $13.99 billion, showing a 5.97% drop compared to the year-ago quarter.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.97 per share and revenue of $63.2 billion. These results would represent year-over-year changes of -4.5% and -0.67%, respectively.
Investors should also note any recent changes to analyst estimates for Pfizer. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.51% higher within the past month. Pfizer presently features a Zacks Rank of #3 (Hold).
Looking at valuation, Pfizer is presently trading at a Forward P/E ratio of 8.87. This valuation marks a discount compared to its industry's average Forward P/E of 14.82.
It's also important to note that PFE currently trades at a PEG ratio of 0.64. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.32.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 69, finds itself in the top 28% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Stock Dips While Market Gains: Key Facts
Pfizer (PFE - Free Report) closed the most recent trading day at $26.21, moving -0.38% from the previous trading session. This move lagged the S&P 500's daily gain of 1.08%. Meanwhile, the Dow gained 0.92%, and the Nasdaq, a tech-heavy index, added 1.41%.
The the stock of drugmaker has risen by 2.93% in the past month, leading the Medical sector's gain of 0.21% and the S&P 500's loss of 8.26%.
The investment community will be closely monitoring the performance of Pfizer in its forthcoming earnings report. On that day, Pfizer is projected to report earnings of $0.67 per share, which would represent a year-over-year decline of 18.29%. Simultaneously, our latest consensus estimate expects the revenue to be $13.99 billion, showing a 5.97% drop compared to the year-ago quarter.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.97 per share and revenue of $63.2 billion. These results would represent year-over-year changes of -4.5% and -0.67%, respectively.
Investors should also note any recent changes to analyst estimates for Pfizer. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.51% higher within the past month. Pfizer presently features a Zacks Rank of #3 (Hold).
Looking at valuation, Pfizer is presently trading at a Forward P/E ratio of 8.87. This valuation marks a discount compared to its industry's average Forward P/E of 14.82.
It's also important to note that PFE currently trades at a PEG ratio of 0.64. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.32.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 69, finds itself in the top 28% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.